Health Strategies Group Key Finding #1 2/28/2019 Health Strategies Group C-Suite Executives Identify the Majority of Biopharmaceutical Relationships as Transactional or Collaborative Out of 1,950 potential relationships with biopharmaceutical companies, c-suite executives classify 24% as Transactional and 26% as Collaborative Sixty-eight percent (68%) of c-suite executives indicate an organizational relationship between their organization and the biopharmaceutical industry Forty-three percent (43%) of respondents report a Collaborative or Partner relationship with biopharmaceutical companies Slight year-to-year variations in the relationship distribution result from adding biopharmaceutical companies to the study and changes to the research panel; however the proportion of Stressed, Transactional, Collaborative, and Partner relationships remains consistent with past years Request slides info@healthstrategies.com